Sanofi’s Split Decision Cost It A Few Billion Overnight

Sanofi’s Split Decision Cost It A Few Billion Overnight
Theodora Lee Joseph, CFA

4 months ago2 mins

What’s going on here?

Sanofi announced plans to spin off its consumer healthcare business, and that cost the French pharmaceutical company a few billion overnight.

What does this mean?

Sanofi’s plan to sell off its consumer healthcare business was never going to make the company a quick buck. Quite the opposite: it’s a long-term game plan that could allow the pharmaceutical firm to pour more cash into drug research. And while that may well pay off in the future, Sanofi did need to sacrifice the 32% profit margin target it had set for 2025 as a result. Next year’s outlook, too, ended up roughly 9% worse than analysts expected. Investors can be patient when they need to be, but not this time: they sent Sanofi’s stock down 16% after the news.

Sanofi stock
Source: Google Finance

Why should I care?

For markets: That’s an expensive decision.

That knock cost Sanofi’s market value €20 billion in a single day, and the firm won’t be able to rest easy for a while. See, investors are already uneasy about companies' risk management during these dicey days of business-bruising high interest rates. What’s more, shaky stock markets and high interest rates aren’t exactly a dream dealmaking environment, which casts some doubt over Sanofi’s ability to make the most of the sale and make decent returns on its resulting investments.

The bigger picture: You win some, you lose some.

In fairness, businesses can’t simply rest on their laurels in this risky environment. Money’s only getting more expensive to borrow, which puts a cap on how much firms can invest in themselves. So while major strategic changes will be painful in the short term, risk-taking companies may emerge from the downturn at the top of the pile. And for investors who manage to spot the most promising strategy adjustments, the future could look just as lucrative.



All the daily investing news and insights you need in one subscription.

Disclaimer: These articles are provided for information purposes only. Occasionally, an opinion about whether to buy or sell a specific investment may be provided. The content is not intended to be a personal recommendation to buy or sell any financial instrument or product, or to adopt any investment strategy as it is not provided based on an assessment of your investing knowledge and experience, your financial situation or your investment objectives. The value of your investments, and the income derived from them, may go down as well as up. You may not get back all the money that you invest. The investments referred to in this article may not be suitable for all investors, and if in doubt, an investor should seek advice from a qualified investment advisor.

/3 Your free quarterly content is about to expire. Uncover the biggest trends and opportunities. Subscribe now for 50%. Cancel anytime.

© Finimize Ltd. 2023. 10328011. 280 Bishopsgate, London, EC2M 4AG